the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: the Study of the Bleeding Risks Stratification Model and Endoscopic Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zhizheng Ge, MD, Ph D
- Email: zhizhengge@aliyun.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Zhizheng Ge, MD. Ph.D
- Phone Number: 18621890923
- Email: zhizhengge@aliyun.com.cn
-
Principal Investigator:
- Zhizheng Ge, MD. Ph.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The patients should sign informed consent and be informed of the specific trial plan;
- The patients should have the China nationality;
- The patients should be aged from 18 to 70 years old, male or female;
- The intestinal vascular lesions should be found by capsule endoscopy, and / or balloon assisted enteroscopy; OR the patients should present with persistent and recurrent bleeding, while the bleeding lesions are unable to be located by all these examinations mention above;
- The patients should present with persistent and recurrent bleeding (>=2 times for one year);
- Hb levels should decreased 10% lower than baseline.
- The patient is willing to comply with the instructions and have the ability to complete the study of research program.
Exclusion Criteria:
patients associated with varicosity due to cirrhosis of the liver; Or patients with uncontrolled hypertension, hyperglycemia, or other severe diseases;
- patients with a history of severe peripheral neuropathy, seizures, rheumatoid immune disease, or thromboembolic disease;
- patients with indications which should constantly use non-steroidal anti-inflammatory drugs, anticoagulants and anti-platelet or acetyl salicylic acid preparation, ginkgo, Echinacea, Chinese herbal medicine composition, other anti-angiogenesis drugs;
- patients with malignant or severe heart disease (uncontrolled angina and/or myocardial infarction, congestive heart failure within 3 months before recruiting, etc.), lung disease (respiratory failure), kidney, pancreatic, liver disease or other diseases that researchers evaluated as affect the judgment of the treatment;
- previously small intestinal bowel resection surgery;
- serious life-threatening gastrointestinal bleeding requiring immediate surgical treatment;
- alcohol and/or drug abuse, addiction or rely on) or the doctor determine compliance claim;
- patients had been recruited into other clinical research within 6 months;
- personnel related to this study;
- patients have no legal behavior ability or self-knowledge; Or patients refuse into groups.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Endoscopic Intervention Group
Endoscopic therapy
|
Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary.
Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC).
Among these options, APC is the most promising.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Participants Whose yearly Rebleeding times Decreased From Baseline by ≥ 50%
Time Frame: up to 3 yrs
|
up to 3 yrs
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference of patients completely cured
Time Frame: up to 3 yrs
|
The cessation of bleeding was defined as repeated negative fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period.
Rebleeding was defined based on a positive FOBT at any visit after treatment
|
up to 3 yrs
|
|
difference in Blood Transfusions Requirements
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference in Total Transfused Red Cell Requirements
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference in yearly bleeding Episodes
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference in yearly mean Hemoglobin (Hb) level
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
numbers of patients requiring hospitalization
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference of yearly hospitalization times
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference of the number of days in hospital yearly
Time Frame: up to 3 yrs
|
up to 3 yrs
|
|
|
difference in mean iron requirements
Time Frame: up to 3 yrs
|
up to 3 yrs
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- rj(2015)088K-b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.